Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC22A12 | Q96S37 | 15/20 | 0.58 |
| ▸ | MEN1 | O00255 | 2/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.51 |
| ▸ | SLC22A6 | Q4U2R8 | 2/20 | 0.51 |
| ▸ | SLC22A8 | Q8TCC7 | 2/20 | 0.51 |
| ▸ | SLC22A11 | Q9NSA0 | 2/20 | 0.51 |
| ▸ | KAT6A | Q92794 | 1/20 | 0.50 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17549760 | 0.84 | ALDH1A1 (0.47) | SLC22A12ALDH1A1 | |
| SCHEMBL6732196 | 0.83 | SLC22A12 (0.57) | SLC22A12MEN1KMT2AALDH1A1CYP2C9 | |
| SCHEMBL17698979 | 0.82 | SLC22A12 (0.60) | SLC22A12MEN1KMT2AALDH1A1CYP2C9 | |
| SCHEMBL422146 | 0.81 | SLC22A12 (0.58) | SLC22A12MEN1KMT2AALDH1A1CYP2C9 | |
| SCHEMBL29536289 | 0.81 | SLC22A12 (0.58) | SLC22A12MEN1KMT2AALDH1A1CYP2C9 | |
| SCHEMBL1767681 | 0.81 | SLC22A12 (0.58) | SLC22A12MEN1KMT2AALDH1A1CYP2C9 | |
| SCHEMBL10143548 | 0.80 | SLC22A12 (0.70) | SLC22A12MEN1KMT2AALDH1A1CYP2C9 | |
| SCHEMBL4731653 | 0.79 | CYP1A2 (0.55) | ALDH1A1 | |
| SCHEMBL3769130 | 0.78 | SLC22A12 (0.70) | SLC22A12MEN1KMT2AALDH1A1CYP2C9 | |
| SCHEMBL515098 | 0.78 | KMT2A (0.56) | SLC22A12MEN1KMT2AALDH1A1CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110857278-B | Method for synthesizing N-methylsulfonamide in water | 南京理工大学 | 2022-04-15 | — | — | CN | disclosed |
| CN-110857278-A | Method for synthesizing N-methylsulfonamide in water | 南京理工大学 | 2020-03-03 | — | — | CN | disclosed |
| US-8772327-B2 | Phenylpropionic acid derivative and use thereof | ASAHI KASEI PHARMA CORPORATION (JP) | 2014-07-08 | — | — | US | disclosed |
| US-20130131134-A1 | PHENYLPROPIONIC ACID DERIVATIVE AND USE THEREOF | MORITA KOHEI (JP) | 2013-05-23 | — | — | US | disclosed |
| US-8334314-B2 | Phenylpropionic acid derivative and use thereof | ASAHI KASEI PHARMA CORPORATION (JP) | 2012-12-18 | — | — | US | disclosed |
| US-20120165309-A1 | HETERO RING DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2012-06-28 | — | — | US | disclosed |
| WO-2010092962-A1 | HETERO RING DERIVATIVE | アステラス製薬株式会社 (JP) | 2010-08-19 | — | — | WO | disclosed |
| US-20100093819-A1 | PHENYLPROPIONIC ACID DERIVATIVE AND USE THEREOF | ASAHI KASEI PHARMA CORPORATION (JP) | 2010-04-15 | — | — | US | disclosed |
| EP-1521744-B1 | ARYLSULPHONAMIDE DERIVATIVES AND USE THEREOF AS B1 BRADYKININ RECEPTOR ANTAGONISTS | FOURNIER LAB SA (FR) | 2009-04-01 | — | — | EP | disclosed |
| US-7361687-B2 | Arylsulphonamide derivatives and methods of preparing | LABORATOIRES FOURNIER SA (FR) | 2008-04-22 | — | — | US | disclosed |
| US-20060084699-A1 | Novel arylsulphonamide derivatives and use thereof as therapeutic agents | LABORATOIRES FOURNIER SA (FR) | 2006-04-20 | — | — | US | disclosed |
| EP-1521744-A1 | ARYLSULPHONAMIDE DERIVATIVES AND USE THEREOF AS B1 BRADYKININ RECEPTOR ANTAGONISTS | LABORATOIRES FOURNIER S.A. (FR) | 2005-04-13 | — | — | EP | disclosed |
| WO-2004085400-A1 | SUBSTITUTED PYRI(MI)DIN(THIO)CARBOXAMIDES USED AS PESTICIDES | BAYER CROPSCIENCE AG (DE) | 2004-10-07 | — | — | WO | disclosed |
| WO-2003106428-A1 | NOVEL ARYLSULPHONAMIDE DERIVATIVES AND USE THEREOF AS THERAPEUTIC AGENTS | LABORATOIRES FOURNIER SA (FR) | 2003-12-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060084699-A1 | Novel arylsulphonamide derivatives and use thereof as therapeutic agents | UGT1A1, UGT2B7, UGT1A6 | SLC22A12 1107/4885MEN1 4618/4885KMT2A 3755/4885 |
| US-20130131134-A1 | PHENYLPROPIONIC ACID DERIVATIVE AND USE THEREOF | PLA2G12A, PLA2G4A, PLA2G4B | SLC22A12 1209/4885MEN1 4753/4885KMT2A 1631/4885 |
| US-20120165309-A1 | HETERO RING DERIVATIVE | IL2, PIK3R2, IL2RA | SLC22A12 2639/4885MEN1 4630/4885KMT2A 1656/4885 |
| US-20100093819-A1 | PHENYLPROPIONIC ACID DERIVATIVE AND USE THEREOF | PLA2G12A, PLA2G4A, PLA2G4B | SLC22A12 1209/4885MEN1 4753/4885KMT2A 1631/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.